ClinicalTrials.gg
Not yet recruitingNCT07945236Updated Nov 18, 2026

FISH Detection of PML::RARA and BCR::ABL1

An observational study in Acute Promyelocytic Leukemia and Chronic Myeloid Leukemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Assiut University · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to establish and evaluate a standardized fluorescence in situ hybridization workflow for detection of PML::RARA in acute promyelocytic leukemia and BCR::ABL1 in chronic myeloid leukemia.

Read the detailed description

Acute promyelocytic leukemia is defined by the PML::RARA fusion, and chronic myeloid leukemia is defined by the BCR::ABL1 fusion. Fluorescence in situ hybridization (FISH) can detect these fusions rapidly on interphase cells.

This observational study will apply a standardized FISH workflow using dual-color dual-fusion probes for PML::RARA and BCR::ABL1. Laboratory-specific normal cut-off values will be established from control specimens, and the probes will be tested on confirmed positive specimens from newly diagnosed untreated patients.

02

Conditions studied

  • Acute Promyelocytic Leukemia
  • Chronic Myeloid Leukemia

Keywords

  • Chronic myeloid leukemia
  • Fluorescence in situ hybridization
  • PML::RARA
  • BCR::ABL1
  • Assiut
  • Acute promyelocytic leukemia
03

In context

Leukemia, Promyelocytic, Acute

135 studies on the registry are indexed under Leukemia, Promyelocytic, Acute; 17 are open to participants now.

This study's planned enrollment of 40 is below the median of 109 across 18 observational studies indexed under Leukemia, Promyelocytic, Acute.

Browse Leukemia, Promyelocytic, Acute studies →

Lead sponsor

Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Newly diagnosed untreated patients with acute promyelocytic leukemia or chronic myeloid leukemia, and individuals without hematologic malignancy who have a normal karyotype, at Assiut University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Newly diagnosed untreated acute promyelocytic leukemia with PML::RARA
  • Newly diagnosed untreated chronic myeloid leukemia with BCR::ABL1
  • Adequate bone marrow or peripheral blood sample
  • Control individuals without hematologic and with normal karyotype
  • Written

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy, all-trans retinoic acid, arsenic trioxide, or tyrosine kinase inhibitors
  • or secondary leukemia
  • Hematologic in control group
  • Refusal of
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Leukemia Patients

    Newly diagnosed untreated patients with acute promyelocytic leukemia or chronic myeloid leukemia.

  • Controls

    Individuals without hematologic malignancy who have a normal karyotype.

06

What researchers measure

Primary outcomes

  1. Number of nuclei showing positive FISH signal pattern

    Number of interphase nuclei showing the expected positive signal pattern for PML::RARA or BCR::ABL1 by fluorescence in situ hybridization (out of 200 nuclei scored per case).

    Time frame: Baseline

Secondary outcomes

  1. Normal cut-off values for FISH signals

    Laboratory-specific normal cut-off values (percentage) for each fluorescence in situ hybridization signal pattern calculated from control specimens using the inverse beta function.

    Time frame: Baseline

  2. Number of cases with typical signal pattern

    Number of confirmed positive cases showing the typical dual-fusion signal pattern by fluorescence in situ hybridization.

    Time frame: Baseline

  3. Inter-observer concordance rate

    Percentage of agreement between two independent scorers for fluorescence in situ hybridization signal patterns.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 26, 2027
CompletionEst.
Mar 10, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945236
Lead sponsor
Assiut University
Responsible party
Amira Ehab Salah Eldin (Assistant Lecturer, Department of Clinical Pathology, Assiut University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 26, 2027 (estimated)
Completion
Mar 10, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Amira E Salah Eldin, Resident
Contact
AmiraEhab@aun.edu.eg
01005305860
Zeinab A Abdel-Hafez, prof
study chair · Clinical pathology Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion